Home » Stocks » Humanigen

Humanigen Inc. (HGEN)

Stock Price: $4.15 USD -0.70 (-14.43%)
Updated Aug 11, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 873.58M
Revenue (ttm) n/a
Net Income (ttm) -10.22M
Shares Out 126.34M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $4.15
Previous Close $4.85
Change ($) -0.70
Change (%) -14.43%
Day's Open 4.86
Day's Range 4.05 - 4.95
Day's Volume 970,764
52-Week Range 0.30 - 6.79

More Stats

Market Cap 873.58M
Enterprise Value 880.75M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 126.34M
Float 55.11M
EPS (basic) -0.09
EPS (diluted) -0.09
FCF / Share -0.03
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 290,378
Short Ratio 0.65
Short % of Float 7.46%
Beta -1.70
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -8.76M
Net Income -10.22M
Free Cash Flow -3.92M
Net Cash -7.18M
Net Cash / Share -0.03
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -942.66%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$64.00*
Low
64.0
Current: $4.15
High
64.0
Target: 64.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue------0.046.1020.2617.71
Revenue Growth-------99.28%-69.89%14.36%-
Gross Profit------0.046.1020.2617.71
Operating Income-8.94-11.48-19.03-27.01-34.35-36.72-40.91-23.48-2.27-6.12
Net Income-10.29-12.00-21.99-27.02-35.38-38.00-41.95-23.51-2.23-5.10
Shares Outstanding11294.7614.989.714.134.123.030.260.240.21
Earnings Per Share-0.09-0.13-1.47-2.78-8.57-9.22-13.84-89.76-9.20-24.16
Operating Cash Flow-4.00-6.21-14.25-20.96-29.06-35.94-38.82-23.91-15.3314.40
Capital Expenditures---0.01-0.02-0.45-0.340.15-0.46-0.07
Free Cash Flow-4.00-6.21-14.25-20.95-29.08-36.39-39.16-23.76-15.7914.33
Cash & Equivalents0.210.890.843.018.6240.9176.9420.5018.0534.24
Total Debt6.493.5019.374.295.4110.939.979.83--
Net Cash / Debt-6.27-2.61-18.53-1.283.2129.9866.9710.6818.0534.24
Assets0.521.371.674.7211.1542.9878.7024.5419.3535.98
Liabilities14.849.4826.019.105.4118.3618.1717.468.5123.21
Book Value-14.32-8.11-24.34-4.385.7324.6160.54-94.94-72.35-70.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Humanigen Inc.
Country United States
Employees 2
CEO Cameron Durrant

Stock Information

Ticker Symbol HGEN
Stock Exchange US OTC
Unique Identifier OTCMKTS: HGEN
IPO Date January 31, 2013

Description

Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase I/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. The company has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase I/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a partnership with Catalent Biologics to manufacture investigational covid-19 therapeutic candidate Lenzilumab. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.